Single-center phase 1-2 study of BMS-986156 with ipilimumab or nivolumab with or without SABR for advanced solid malignancies

BMS-986156 is an agonist of the glucocorticoid-induced tumor necrosis factor receptor (TNFR)-related protein and promotes increased effector T-cell activation. A phase 1-2 study at MD Anderson Cancer Center (Houston, TX) evaluated BMS-986156 in combination with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy (SABR) among patients with stage IV solid malignancies resistant to standard treatments.The treatment was tolerated, with 10% of patients discontinuing due to treatment-related adverse events, 44% experiencing grade 1-3 TRAEs, and no patients with grade 4 or 5 TRAEs. Among the patients who were evaluable for efficacy, 48.7% had stable disease and 7.7% had partial response Abscopal disease control rate was 38.5% and abscopal response rate was 7.7%. The authors conclude that BMS-986156 in combination with ipilimumab or nivolumab with or without SABR was well-tolerated and had encouraging activity among patients with advanced solid tumors resistant to standard treatments.